Joint Symposium 19
Oncology & Theranostics Committee / European Hematology Association (EHA)
Tuesday, October 15, 11:30-13:00

Session Title
PET/CT Guided Treatment in Non-Hodgkin Lymphoma

Chairpersons
Josée Zijlstra (Amsterdam, Netherlands / EHA)
Carsten Kobe (Cologne, Germany)

Programme
11:30 - 12:00 Josée Zijlstra (Amsterdam, Netherlands / EHA): Response Assessment - The Haematologist’s Perspective

12:00 - 12:30 George Mikhaeel (London, United Kingdom): Staging - The Radiotherapist’s Perspective

12:30 - 13:00 Anne Segolène Cottereau (Paris, France): Impact of Metabolic Tumour Volume

Educational Objectives
1. To understand how PET/CT is used to guide chemotherapy in Non-Hodgkin Lymphoma
2. To understand how PET/CT is used to guide radiotherapy in Non-Hodgkin Lymphoma
3. To learn how to use metabolic tumor volume for further therapy optimization

Summary
Response assessment using PET/CT is important to guide and to monitor chemotherapy in Non-Hodgkin Lymphoma. PET/CT in staging is essential for accurate radiotherapy. Furthermore, metabolic volume will be able to provide more predictive and prognostic information.

Key Words
PET/CT, FDG, Radiotherapy, Chemotherapy, Non-Hodgkin Lymphoma